Diagnostic Criteria of ARDS at High Altitudes in Western China

ARDS Clinical Trial

Official title:

Diagnostic Criteria of ARDS at High Altitudes in Western China

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04215666
• Other study ID #: ARDS Criteria high altitudes
• Status: Recruiting
• Start date: December 1, 2019
• Est. completion date: December 31, 2022

Study information

• Verified date: December 2019
• Source: Affiliated Hospital of Qinghai University
• Contact: Gan Guifen, Bachelor
• Phone: 15897083336
• Email: xzhd1991[@]163.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The severity of ARDS in high altitude areas was classified according to the Berlin standard high altitude area Oxygenation.

Description:

Will between January 2018 and December 2018 in lanzhou, and so on more than 1500 meters above sea level in qinghai region 10 intensive care patients with ARDS, respectively according to the standard in Berlin, Berlin, diagnosis of high altitude ARDS calibration standards and zhang the plateau region in western China put forward by the diagnosis of ALI/ARDS severity classification, observation group patients were ICU mortality, within 28 days, ICU mortality did not use breathing machine time, mechanical ventilation, ICU length of hospital stay, and the differences in hospitalization days.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3000
• Est. completion date: December 31, 2022
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• age =18

• the primary disease of ARDS caused by systemic infection, shock, severe pneumonia, aspiration and trauma

• blood gas analysis showed a progressive decline in pulmonary ventilation function

• PEEP=5cmH2O Exclusion criteria

• Receive a large amount of hormone shock therapy in a short period of time

• Died within a short time (< 24h) after mechanical ventilation

• Lack of data

• No chest imaging data

Related Conditions & MeSH terms

• ARDS

Locations

Country	Name	City	State
China	Affiliated hospital of qinghai university	Xining	Qinghai

Sponsors (2)

Lead Sponsor	Collaborator
Affiliated Hospital of Qinghai University	Children's Hospital of Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ICU mortality	mortality during treatment in ICU	up to 24 weeks
Primary	28 days mortality	mortality at 28 days of hospitalization	up to 24 weeks
Secondary	Ventilator Free time	No ventilator use time in ICU	up to 24 weeks
Secondary	Ventilator time	Ventilator time in ICU	up to 24 weeks